# MedCap > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/medcap). ## Overview MedCap is a Swedish investment and operating group that acquires and develops niche life science companies through majority-owned subsidiaries. Its portfolio is organized into three business areas: Assistive Tech, MedTech and Specialty Pharma, with companies run under their own brands but supported by group-level ownership and governance. ## Products & services • Assistive technology products and solutions • Medical technology devices, software and components • Packaging solutions for life science products • Specialty pharmaceutical products and related operations • Acquisition, ownership and development of niche life science companies - **Assistive Tech** (35%) — Assistive technology businesses serving users and care environments with specialized products. - **MedTech** (40%) — Medical technology products, software, components and packaging solutions for healthcare and life science customers. - **Specialty Pharma** (25%) — Specialty pharmaceutical operations focused on niche products and related commercial activities. - Assistive technology products and solutions - Medical technology devices, software and components - Packaging solutions for life science products - Specialty pharmaceutical products and related operations - Acquisition, ownership and development of niche life science companies ## Customers MedCap sells through its operating subsidiaries to healthcare and life science end markets rather than to a single end customer type. Buyers include regions, hospitals, medtech companies, and nutrition and pharmaceutical companies, depending on the business area. The portfolio is built around niche products where customers value specialization, reliability and application-specific support. - **Regions and public healthcare systems** (primary) — Buy assistive technology and related solutions for care delivery and patient support. - **Hospitals and care providers** (primary) — Purchase medical technology products and software used in clinical workflows. - **Medtech manufacturers** (secondary) — Source components and packaging solutions that support device production and compliance. - **Nutrition and pharmaceutical companies** (secondary) — Buy packaging and related life science solutions for regulated products. - **Specialty pharma end markets** (secondary) — Use niche pharmaceutical products distributed through the group’s pharma operations. - Regions and public healthcare buyers purchasing assistive solutions - Hospitals buying medical technology products and software - Medtech manufacturers sourcing components and packaging - Nutrition and pharmaceutical companies buying packaging solutions - Specialty pharma customers and channel partners for niche products ## Geography MedCap is headquartered in Stockholm and operates as a Nordic life science owner with companies based mainly in northern Europe. The group actively seeks acquisitions in Europe and its subsidiaries serve international markets, so revenue and supply chains are exposed to cross-border demand, currency and trade conditions. Its operating footprint is decentralized, with each subsidiary run under its own brand while benefiting from group-wide support. - Headquartered in Stockholm, Sweden - Core acquisition focus is companies based in northern Europe - Subsidiaries serve international markets beyond the Nordics - Operations are decentralized across independent portfolio companies - Cross-border sales and sourcing create currency and trade exposure ## Strategy MedCap’s strategy is to acquire profitable niche life science companies and develop them through active ownership, decentralized governance and group-level support. Growth is driven by add-on acquisitions, new core holdings in northern Europe and operational development within existing subsidiaries. - **Pursue acquisitions in niche life science** (short-term) — Acquisitions are a core growth engine and expand the portfolio. - **Develop existing portfolio companies** (medium-term) — Operational support and synergies are intended to improve each subsidiary's potential. - **Use balance sheet capacity for growth** (medium-term) — Financial flexibility supports continued deal-making and portfolio expansion. - Acquire profitable niche life science companies with growth potential - Use add-on acquisitions to expand existing subsidiaries - Build new core holdings in northern Europe - Support founders and management with capital, networks and expertise - Maintain a decentralized model with local brands and group synergies ## Risks MedCap is exposed to sector concentration risk because its portfolio is focused on pharmaceuticals, medical technology and assistive technology. Its acquisition-led model also creates execution risk around deal sourcing, integration, contingent consideration and the performance of individual holdings. As a Nordic group with international sales and supply chains, it faces currency, trade and geopolitical risks that can affect demand and sourcing. - **Sector and portfolio concentration** [high] — The group is concentrated in pharmaceuticals, medtech and assistive tech, so setbacks in one holding can matter. - **Acquisition and integration risk** [high] — Growth depends on buying and developing companies, which can lead to valuation, integration and execution issues. - **Currency and trade exposure** [medium] — Sales and purchases span multiple countries, creating FX and tariff sensitivity. - **Customer concentration in niche businesses** [medium] — Smaller specialized companies can depend on a limited number of large customers or channels. - Concentration in life science sectors and individual portfolio companies - Acquisition execution and integration risk across new holdings - Currency and short-term price risk from cross-border sales and purchases - Loss of major customers in niche operating companies - Geopolitical and trade uncertainty affecting demand and supply chains ## Accounting The most important accounting judgments for MedCap relate to acquisition accounting, contingent consideration and the valuation of portfolio-related liabilities. IFRS 16 also affects reported leverage and operating performance comparisons, while the decentralized portfolio structure makes goodwill and intangible asset impairment a recurring watch item. Because the group uses non-IFRS measures such as adjusted EBITA, investors should separate operating trends from acquisition-related and fair value effects. - **Contingent consideration fair value** — Can move reported earnings and net debt - **Goodwill and intangible asset impairment** — Potential write-downs if portfolio companies underperform - **IFRS 16 lease accounting** — Changes reported net debt and EBITDA-based measures - **Adjusted EBITA and items affecting comparability** — Important for comparing acquisition-driven growth with recurring earnings - Contingent consideration is measured at fair value and revalued through profit or loss - Acquisition accounting affects goodwill and intangible asset balances - IFRS 16 changes reported debt and EBITDA-style comparisons - Adjusted EBITA excludes items affecting comparability - Non-IFRS measures require reconciliation to IFRS results --- *Last updated: 2026-08-11T04:04:54.134187+00:00*